Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cefzil
CEFZIL · 1 trial · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cefzil® 500 mg tablets | DRUG | 1 x 500 mg, single-dose fasting |
| Cefprozil 500 mg Tablets | DRUG | 1 x 500 mg, single-dose fasting |
Inclusion Criteria: * Subjects selected for this study will be non-smokers at least 18 years of age. Subjects will have a BMI (body mass index) of 30 or less. * Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is no...
CEFZIL is a brand of cefprozil, an oral antibiotic. Its listed development program covers an undisclosed indication, and the only trial on record enrolled healthy adult volunteers rather than patients. The drug is studied as a small molecule and is not described as approved for any specific indication in this program.
CEFZIL is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the company associated with the CEFZIL brand and its listed oral suspension and tablet presentations.
CEFZIL is listed at Phase 1. One trial has been completed and none are active, with a total enrollment of 38 participants. The program is investigational and remains in clinical development.
CEFZIL has one recorded trial, NCT00840281, titled Cefprozil 500 mg Tablets Under Fasting Conditions. It was a completed Phase 1 study of 38 healthy volunteers in the United States, randomized and active controlled, with participants aged 18 years and older.
Yes. CEFZIL is a brand name for cefprozil, and the listed alternative names include CEFZIL for Oral Suspension 250 mg/5mL, Cefzil 500 mg tablets, and Cefzil. Searches for any of these names refer to the same product.
CEFZIL is a small molecule, and its listed development program does not specify a molecular target or target class. The completed Phase 1 trial, NCT00840281, evaluated cefprozil 500 mg tablets under fasting conditions in healthy volunteers rather than testing a named target.